目的对乙酰半胱氨酸胶囊的处方进行筛选,制备乙酰半胱氨酸胶囊,测定其含量。方法对乙酰半胱氨酸胶囊的处方进行筛选,高效液相色谱法测定含量,流动相:0.68%磷酸氢二钾溶液(用磷酸调节pH值至3.0)-甲醇=95∶5;检测波长为214 nm,进样量:10μL。结果乙酰半胱氨酸200 g、微晶纤维素50 g,0.5%羟丙基甲基纤维素(75%乙醇溶)为最佳处方。乙酰半胱氨酸在0.1274~0.4248 mg/mL之间呈良好的线性关系(r=0.9996,n=5),平均回收率为99.53%,RSD%为1.60%(n=9)。结论该制剂制备工艺合理可行,含量测定方法准确可靠。

Objective To screen the prescription of acetylcysteine capsules, and to prepare the acetylcysteine capsules and to determine of its content. Method To screen the prescription of acetylcysteine capsules. The analysis was performed by HPLC, a mobile phase of 0.2mol/L buffer stock solution(pH=3.0)-methanol(95∶5)with a flow rate at 1 mL/min. The UV detective wavelength was 214 nm.Results Prescription was made up by 200g acetylcysteine, 50 g Microcrystalline cellulose and 0.5% HPMC. Acetylcysteine was linear in the range of 0.1274~0.4248 mg/mL(r=0.9996, n=5).The average recovery was 99.53%(RSD 1.60%, n=9).Conclusion Method for the preparation and quality control of acetylcysteine capsules is reliable.

慢性阻塞性肺疾病(简称慢阻肺)是威胁人类健康的重要疾病,氧化应激和黏液高分泌在其发病机制中具有重要作用.N-乙酰半胱氨酸是一种有效黏液溶解剂,可降低痰液黏度和弹性,改善黏液纤毛清除功能并调节炎症反应.此外,N-乙酰半胱氨酸还具有直接和间接抗氧化特性,这对于慢阻肺患者长期管理可能具有重要意义.本研究拟探讨高剂量的N-乙酰半胱氨酸(600 mg,2次/d)是否能为慢阻肺患者提供更好的有效治疗.

@@

慢性阻塞性肺疾病的发病与气道、肺实质和肺血管的慢性炎症、肺部的蛋白酶和抗蛋白酶失衡、氧化与抗氧化失衡等有关.其中氧化/抗氧化失衡是造成慢性阻塞性肺疾病慢性全身损伤的重要原因.N-乙酰半胱氨酸具有抗氧化及细胞保护作用,本文对近年来N-乙酰半胱氨酸治疗慢性阻塞性肺疾病的研究进展作一综述.

The pathogenesis of chronic obstructive pulmonary disease (COPD) is related to chronic inflammation of airway,lung parenchyma and lung vascular,imbalance of anti-protease and protease,as well as imbalance of oxidation and antioxidation in the lung.Oxidation and antioxidation imbalance is one of the most important reasons for systemic manifestations of COPD.N-acetylcysteine might provide antioxidation and cell protection.In this review article,we will summarize the research progress of Nacetylcysteine in the treatment of COPD.

目的对亚硒酸钠诱导白内障大鼠采用N-乙酰半胱氨酸进行预防性治疗,探讨N-乙酰半胱氨酸对白内障大鼠模型氧化损伤和晶状体浑浊程度的影响。方法 30只SD乳鼠随机分为3组,模型组ip 3.46 mg/kg亚硒酸钠溶液造模后,ip 0.1mL/10 g生理盐水;实验组ip N-乙酰半胱氨酸10 mg/g,30 min ip亚硒酸钠溶液造模;对照组ip 0.1 mL/10 g生理盐水。所有动物均为隔日注射,连续6次。比较大鼠晶状体浑浊程度和SOD活性、NOS活性和MDA水平。结果在晶状体核区、后囊区、前囊区+后囊区、前囊区+皮质区+核区+后囊区中,实验组与模型组比较得分差异具有统计学意义(P0.05);实验组SOD活性和MDA活性与模型组比较差异均具有统计学意义(P0.05)。结论 N-乙酰半胱氨酸能够预防后囊和核区白内障的发生,其作用是通过减少MDA水平、提高SOD活性、改善氧化应激实现的。

Objective To useN-acetylcysteine for preventive treatment of cataract in rats induced by sodium selenite, and to investigate the preventive effect ofN-acetylcysteine on oxidative damage and degree of lens opacity in cataract model of rats.Methods Thirty SD rats were randomly divided into three groups, the rats in model group were ip injected with 3.46 mg/kg sodium selenite for modeling, then 0.1 mL/10 g ip injection of physiological saline; The rats in experimental group received ip injection of N-acetylcysteine 10 mg/g, 30 min ip injection of sodium selenite for modeling; The rats in control group were ip injected with 0.1 mL/10 g of saline. All rats were injected every other day, 6 times in a row. The lens turbidity degree, SOD activity, NOS activity, and MDA level of rats were compared.Results In the lens nucleus, posterior capsule, anterior capsular area + posterior capsular area, anterior capsular area, and cortex + core + posterior capsule area, the difference of score of the exp

目的：探讨在慢性支气管炎患者中对n-乙酰半胱氨酸及盐酸氨溴索进行联用治疗的效果。方法选取2011至2013年我院收治的66例慢性支气管炎患者作为本次研究的对象，并以随机数字表法方式将其分成2组，每组33例，将其中单纯性实施盐酸氨溴索治疗者归为对照组，将在此条件下施加n-乙酰半胱氨酸治疗者归为观察组，评估两组病例的临床治疗情况，总结治疗经验。结果观察组治疗后可取得93.9%的临床疗效，较之对照组的75.8%更为理想，比较差异明显（P＜0.05）；并且治疗期间，两组病例均无严重不适症状出现。结论为慢性支气管炎患者提供n-乙酰半胱氨酸及盐酸氨溴索联用治疗有确切效果，能够尽早帮助患者解除症状，安全性可靠，适合在今后的临床上普及应用。

Objective to investigate the effects on n-acetylcysteine combined with ambroxol in the treatment of patients with chronic bronchitis.Methods 66 cases of patients with chronic bronchitis were selected in our hospital from 2011 to 2013 as the object of this study, and they were randomly divided into two groups, each 33 cases. Patients treated with ambroxol hydrochloride were classiifed as control group, and patients applied N-acetylcysteine on the base of ambroxol hydrochloride treatment were classiifed as observation group. The effects of clinical treatment in two groups were evaluated, and the experience in the treatment of this condition was summarized.Results After treatment, the clinical efifcacy of 93.9% can be obtained in the observation group, and compared with 75.8% in the control group showing better treatment effect. There was a signiifcant difference (P <0.05); and during treatment period, two groups patients showed no serious symptoms.Conclusion Patients with chronic bronchi